Rezolute Receives Orphan-Drug Designation from FDA for Low Blood Sugar Treatment
Rezolute has been granted an orphan-drug designation by the FDA for its hypoglycemia treatment caused by insulin-producing tumors. The treatment, ersodetug, is set to begin Phase 3 trials in 2025 for tumor hyperinsulinism.